Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research from Dr Richard Williams’ group at the Kennedy Institute suggests a route for the development of more selective – and effective – therapies for immune-mediated inflammatory disease.

Artists representation of T lymphoyctes. Signalling through TNFR2 receptor maintains Foxp3 expression in suppressor T lymphocytes.

Anti-TNF therapy is used to treat millions of patients worldwide for rheumatoid arthritis and other immune-mediated inflammatory diseases (IMIDs). Current anti-TNF therapies block both receptors for TNF - TNFR1 and TNFR2. However, new work from Dr Richard Williams’ lab suggests the development of therapies that specifically block TNFR1 could be advantageous for treating IMIDs.

The Williams lab found that TNFR2 plays a role in limiting the severity and duration of arthritis in animal models. Signalling through TNFR2 prevented methylation of the gene encoding Foxp3, a key protein for maintaining suppressor T regulatory cells that promote immune homeostasis.  

Richard said: “This research has been a great team effort and the results exemplify the complexities of cytokine biology. Thus, one molecule, TNF, can have completely opposing effects, depending on which receptor it acts upon.”

Although biologics targeting TNF have improved the lives of millions of people living with IMIDs, not all patients respond adequately to therapy. The new work suggests an approach to develop more selective therapies to increase efficacy and reduce side effects. 

Richard explains, “This research is likely to further stimulate the clinical development of novel biologics for IMIDs that specifically target TNFR1, whilst sparing TNFR2 signalling. In addition, the finding that TNFR2 controls the activity of regulatory T cells may have implications for cancer therapy as these cells are thought to contribute to immunosuppression within the tumour microenvironment.” 

The work was supported by funding from the Chang Gung Memorial Hospital and the Ministry of Science and Technology, Taiwan. 

Similar stories

New therapeutic target identified in spondyloarthritis

Kennedy

A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.

Researchers identify link in the treatment of inflammatory bowel disease (IBD)

Kennedy

A new study published in the Journal of Experimental Medicine reveals how IL-10 and PGE2 work together to prevent inflammatory tissue damage and maintain a healthy gut balance

Naturally occurring compound spermidine boosts vaccine responses in old mice

Kennedy

A new study by Kennedy Institute's Professor Katja Simon, and colleagues published in Molecular Cell shows that spermidine, a naturally occurring metabolite found in most human cell types, boosts antibody production in both old mice and immune cells from the elderly.

Dialling down inflammation in psoriasis

Kennedy

A collaborative study between the Kennedy Institute and MRC Weatherall Institute of Molecular Medicine (MRC WIMM) identifies a new pathway that limits the severity of inflammatory skin disease.

Geometry is key to T-cell triggering

Kennedy

Kennedy researchers and Columbia University engineers discover geometric underpinnings of T-cell stimulation through precise engineering of T-cell receptor geometry, building a 3D nanofabricated biomimetic surface that simulates the key components of an antigen-presenting cell.